Xponance, Inc. Acadia Pharmaceuticals Inc Transaction History
Xponance, Inc.
- $11.7 Billion
- Q2 2025
A detailed history of Xponance, Inc. transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Xponance, Inc. holds 10,910 shares of ACAD stock, worth $228,455. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,910
Previous 11,585
5.83%
Holding current value
$228,455
Previous $192,000
22.4%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding ACAD
# of Institutions
348Shares Held
163MCall Options Held
811KPut Options Held
334K-
Baker Bros. Advisors LP New York, NY42.9MShares$898 Million9.38% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.3MShares$320 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$253 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY9MShares$188 Million2.98% of portfolio
-
State Street Corp Boston, MA6.18MShares$129 Million0.01% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.39B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...